Alzheimer’s Treatment Enters a New Era: Drugs, Blood Tests and Clinical-Trial Challenges

Alzheimer's Treatment Just Changed. Here's What Comes Next

Estimated reading time: 12 minutes

Key Takeaways

• Two drugs, lecanemab and donanemab, modestly slow early Alzheimer's.
• New blood tests could make diagnosis easier and earlier.
• Up to 45% of dementia cases might be delayed or prevented by fixing risk factors.
• The biggest hurdles now are access, cost, and who gets to join research.

For decades, an Alzheimer's diagnosis felt like a dead end. Doctors could ease some symptoms, but they could not slow the disease itself.

That story is shifting. The 2026 World Alzheimer Report, published by Alzheimer's Disease International (ADI) on September 21, 2026, says Alzheimer's is "no longer universally described as untreatable." This is not a cure, and the report is clear about that. But many experts see it as a real Alzheimer's treatment breakthrough: the first time science has shown it can change the course of the disease, even a little.

This guide explains what changed, what the new drugs can and cannot do, and how blood tests may help people get diagnosed sooner. It also covers the biggest problem left: getting these tools to the people who need them.

In short:

• Two drugs, lecanemab and donanemab, modestly slow early Alzheimer's.
• New blood tests could make diagnosis easier and earlier.
• Up to 45% of dementia cases might be delayed or prevented by fixing risk factors.
• The biggest hurdles now are access, cost, and who gets to join research.

Source: World Alzheimer Report 2026

Lecanemab and Donanemab: The First Drugs to Slow Alzheimer's

The biggest change is the arrival of two medicines: lecanemab and donanemab. They are the first fully approved drugs shown to slow early Alzheimer's, rather than just easing symptoms.

The US Food and Drug Administration (FDA) approved lecanemab in 2023 and donanemab in 2024. The European Commission approved donanemab in July 2025.

How these drugs work

Both are called anti-amyloid antibodies. In Alzheimer's, a sticky protein called amyloid builds up in the brain. These drugs help the body clear some of it. They are given through an infusion, which means a drip into a vein.

What the trials found

The results are real but modest:

• Lecanemab: In the Clarity AD trial, people on the drug declined a little more slowly. The gap was 0.45 points on a memory and daily-living scale (CDR-SB) after 18 months.
• Donanemab: In the TRAILBLAZER-ALZ 2 trial, the gap was 3.25 points on another scale (iADRS) after 76 weeks. This was in people with low or medium levels of a protein called tau.

Think of it as slowing a car, not stopping it. The drugs buy time, but they do not turn back the clock.

Why experts still call it a big moment

Cath Mummery, director of the UK's Dementia Trials Network, said in the report: "What you really hoped for was a bigger effect, but it was a huge moment because it showed you could change the course of the disease." She called it "the first brick," with "an awful lot to build on."

Between 2000 and 2020, more than 99% of experimental dementia drugs failed in clinical trials. Against that record, even a small win matters.

The risks you should know

These drugs carry real safety concerns. The main one is called ARIA, which stands for amyloid-related imaging abnormalities. It usually means swelling in the brain (ARIA-E). Most cases are mild, but some can be serious.

In the main trials, ARIA-E happened in:

• 12.6% of people taking lecanemab
• 24.0% of people taking donanemab

Because of this, doctors need:

• A test confirming amyloid is present in the brain
• Advice about genetic risk, including a gene called APOE
• Regular MRI scans to watch for swelling
• Clinics set up for infusions and for managing side effects

Not everyone agrees on the benefit

Some researchers doubt the drugs give meaningful benefits to patients. Studies suggest they may not work the same way for every person or in every part of the brain. The ADI report accepts this debate but argues the approvals changed what researchers believe is possible.

A useful comparison

The report compares today to cancer research in the 1990s. The first cancer drugs were imperfect, but they opened the door to drug combinations, precision medicine, and earlier treatment. The authors say dementia may be at the same starting line.

They also write that there is "no single breakthrough to rival the discovery of penicillin." Instead, they describe "something quieter… a shift from cure to prevention, from molecule to lifestyle, from inevitability to possibility."

Sources: ADI World Alzheimer Report 2026 | PubMed trial data | European Medicines Agency: Kisunla | NIHR summary of the report

The Alzheimer's Blood Test: Faster Answers Without a Spinal Tap

Drugs only help if people are diagnosed in time. That is why the Alzheimer's blood test may be as important as the medicines themselves.

The diagnosis problem today

The "gold standard" tests for Alzheimer's are brain scans (PET scans) and spinal fluid tests. They are costly, and few places offer them. In the United Kingdom, only about 2% of people diagnosed with Alzheimer's have access to a gold-standard test, according to a study co-led by Jonathan Schott of Alzheimer's Research UK.

The window to treat Alzheimer's is small. Neuroradiologist Emer MacSweeney told ADI: "The biggest mistake that's happening at the minute is people who are clearly, obviously, most likely in the early stages of Alzheimer's, being ignored and completely missed… because that window of opportunity is really small for treatment."

New blood tests are arriving

Blood tests look for biomarkers, which are signs of disease in the blood. Two recent FDA clearances stand out:

Roche Elecsys pTau217 plasma test (cleared August 24, 2026)

• For adults aged 55 and older with signs or complaints of memory or thinking decline
• Helps rule in or rule out amyloid changes in the brain
• Used together with a doctor's assessment, not as a stand-alone diagnosis

PrecivityAD2

• For adults as young as 40 with memory or thinking symptoms
• Measures amyloid and tau markers in a single blood draw
• In a study of 1,142 adults with symptoms, it had a positive predictive value of 97.6% and a negative predictive value of 93.1% compared with established methods

In plain words: when the test says "yes," it was right about 98 times out of 100. When it said "no," it was right about 93 times out of 100.

Why this matters for younger patients

Early-onset Alzheimer's is often missed or misdiagnosed. Symptoms can be mistaken for stress, depression, or other conditions. A test that works from age 40 could shorten the long wait for answers.

Clinically ready, but payers are not

Having a cleared test does not mean everyone can get it. A Milken Institute readiness survey rated diagnostic positioning at Level 4 out of 5. But payer acceptance, meaning insurance and health-system coverage, was only Level 2.

Experts describe the market as "clinically ready but payer-unready." Key open questions include:

• Who pays for the test?
• Do labs have enough capacity?
• Are family doctors trained to read the results?
• Will rural and low-income communities get fair access?

The test still needs real-world proof

Blood tests look promising, but they still need testing at a population level. Researchers must show they can find early cognitive decline in everyday settings, not just in studies.

The ADI report puts the stakes clearly: "A breakthrough drug means little if the majority of people living with dementia are never identified in the first place." It adds that dementia care may depend "as much on family doctors in Havana, Lima, or Bangalore as on billion-dollar laboratories in California."

Sources: Roche: FDA clears Elecsys pTau217 | AJMC: young-onset Alzheimer's often misdiagnosed | Milken Institute blood biomarker summary | ADI World Alzheimer Report 2026

Stop Losing Hours to Work a System Could Do for You
Every manual task you repeat is time you cannot spend on growth. Flowgrammer builds business automation that handles the busywork for you. That includes data entry, follow-ups, reporting, and routine admin. Your team gets hours back, errors drop, and your business scales without hiring for every new task.

👉 Automate your business with Flowgrammer

Dementia Clinical Trials: A Bigger Pipeline and a Big Bottleneck

The third big shift is the sheer amount of research. Dementia clinical trials are now running at a scale never seen before.

The numbers

According to the ADI report:

• Researchers are testing 158 potential therapies across 192 clinical trials worldwide.
• The number of candidate medicines has grown by about 40% over the past decade.
• About eight Phase III trials should report results this year.

Phase III trials are the final, largest tests. They compare a new treatment with standard care in many people.

The people problem

Here is the hidden catch. The current Alzheimer's pipeline needs about 54,728 participants. Of those, 38,417 are needed for Phase III trials alone.

That is a huge number of volunteers. Recruiting and keeping them may be as hard as inventing the drugs. A pipeline full of ideas does not help if trials cannot find enough people to test them.

Why many people never hear about trials

MacSweeney says many patients are never told that trials or new medicines exist. She said: "This is a pandemic. We need a change in mindset in the medical profession to ensure more people are told about clinical trials and supported to join them. We need action, not rhetoric."

The report's main recommendation is that joining a trial should be more inclusive, easier to access, and routine. It should not depend on "persistence or good fortune."

Who is left out

Trial volunteers often do not reflect the real world. Experts at the Alzheimer's Association International Conference (AAIC) 2026 pointed to barriers faced by Black, Hispanic, Indigenous, Asian, and LGBTQ+ communities:

• Distrust of the medical system
• Travel and transport costs
• Language barriers
• Health inequalities
• Trial sites that are far from home

Why diversity is a science problem, not just a fairness one

If trials leave out large groups, results may not apply to everyone. Safety problems can be missed. Drugs may also be less trusted and less used later.

Ideas to fix this include:

• Running trials in community settings
• Using materials that fit different cultures and languages
• Paying or reimbursing participants fairly
• Opening local treatment sites closer to where people live

What the report covers

The 2026 report has seven chapters and five case studies. It looks at recruiting and keeping participants, ethics, safety, global representation, and how aware doctors are of trials. It is a guide to making research work better, not just a list of drugs.

Sources: ADI World Alzheimer Report 2026 | NIHR Dementia Researcher summary | Clinical Trials Arena: AAIC 2026 diversity

Dementia Risk Reduction: Up to 45% of Cases May Be Delayed or Prevented

Drugs are only one part of the story. Prevention may help even more people. This is where the Alzheimer's treatment breakthrough story turns to everyday life.

The WHO's 2026 guidance

In July 2026, the World Health Organization (WHO) updated its guidelines on reducing dementia risk. It treats prevention as a public-health job that spans a whole lifetime. The WHO says up to 45% of dementia cases could be prevented or delayed by tackling modifiable risk factors. These are things people and governments can change.

Key risk factors

The research points to 14 factors. They include:

• High blood pressure (hypertension)
• Diabetes
• High cholesterol
• Smoking and tobacco use
• Too much alcohol
• Physical inactivity
• Depression
• Social isolation
• Air pollution

What the WHO recommends

• Stay physically active.
• Keep your mind and social life active.
• Control blood pressure, blood sugar, and cholesterol.
• Avoid tobacco and limit alcohol.

The WHO also gives a caution. It advises against routine vitamin, omega-3, or multivitamin supplements to prevent dementia unless a person has a diagnosed deficiency. Healthy habits matter more than pills from a shop shelf.

Why small delays add up

Some estimates say 139 million people could be living with dementia by 2050. Even a modest delay in when symptoms begin could mean millions fewer cases. If someone develops dementia five years later, that is five more years of independence for them and their family.

A shift in thinking

For years, people saw dementia as a natural part of getting old. The report calls this "inevitability." Prevention thinking replaces it with "possibility." Heart health, mental health, hearing, and community all play a role in brain health.

Sources: WHO: up to 45% of dementia risk could be prevented or delayed | ADI World Alzheimer Report 2026

The Real Challenge: Getting New Alzheimer's Tools to Patients

Science is moving fast. Health systems are not. The report's main warning is that progress in the lab must be matched by progress in the clinic.

Four gaps that hold things back

1. Diagnosis gap
Many people are never tested. Without a diagnosis, they cannot get a drug, join a trial, or plan ahead.

2. Payment gap
Approval does not equal coverage. If insurers or health systems will not pay, patients may never receive tests or treatments.

3. Workforce gap
Family doctors need training to spot early signs, order the right tests, and explain options. Specialist clinics need staff for infusions and MRI monitoring.

4. Equity gap
Most research and care are concentrated in wealthy places and in certain groups. The report says the future of dementia care could depend on doctors in places like Havana, Lima, and Bangalore.

What a good system might look like

1. A person notices memory changes and visits a family doctor.
2. The doctor offers a simple blood test.
3. If the test suggests Alzheimer's, the person is referred for further checks.
4. The care team explains treatment options, risks, and clinical trials.
5. The patient and family decide together what to do.

This path is not common today. Building it is the "next decade" job the report describes.

A fair view of the limits

It helps to stay realistic:

• A cure is still far away, though the report says it "feels like a more palpable prospect than ever before."
• The new drugs help only some people, mostly those in the early stages.
• Side effects need careful monitoring.
• Blood tests support a doctor's judgment but do not replace it.

Sources: ADI World Alzheimer Report 2026 | Milken Institute | PubMed

What Patients and Families Can Do Now

You do not need to wait for the system to catch up. Here are practical steps.

If you are worried about memory changes

• Book a check-up early. The treatment window is short, so do not wait.
• Write down changes. Note what you or your loved one has forgotten, and when it began.
• Ask about blood tests. Ask whether a blood biomarker test is available where you live.
• Bring someone along. A family member can help recall details and ask questions.

Questions to ask your doctor

• Could this be early Alzheimer's, or another cause?
• Is a blood test, brain scan, or other test right for me?
• Am I a candidate for lecanemab or donanemab? What are the risks?
• Are there clinical trials near me?
• What can I do about blood pressure, diabetes, and cholesterol?

Lower your own risk

• Move your body most days.
• Keep your blood pressure, blood sugar, and cholesterol in check.
• Stop smoking and cut back on alcohol.
• Stay connected with friends and family.
• Treat depression and protect your hearing.
• Keep learning new things.

Consider joining a trial

Trials give people early access to new ideas and help future patients. If you are interested, ask your doctor or a local dementia organization. Researchers especially need volunteers from groups often left out of studies.

Sources: WHO guidance | ADI World Alzheimer Report 2026 | Clinical Trials Arena

The Bottom Line

Alzheimer's has entered a new chapter. It is a disease-modifying era, but not a curative one.

• Two approved drugs can slow early disease a little, with real safety risks.
• New blood tests may make diagnosis faster and cheaper.
• Hundreds of trials are testing new medicines, but they need tens of thousands of volunteers.
• Up to 45% of dementia cases might be delayed or prevented through healthier living.
• The biggest challenge now is access, fairness, and speed of delivery.

The report ends with a hopeful challenge: taking part in dementia research should become "a realistic opportunity for everyone who wishes to consider it." If science and health systems keep pace, this could be the start of a much better story for millions of families.

Source: ADI World Alzheimer Report 2026

Frequently Asked Questions

1. Is Alzheimer's disease now curable?

No. The 2026 World Alzheimer Report says a cure is still far away. What has changed is that Alzheimer's is no longer seen as completely untreatable. Some drugs can modestly slow early disease.

2. What are lecanemab and donanemab?

They are anti-amyloid antibody drugs given by infusion. They help clear a sticky protein called amyloid from the brain. They were the first fully approved drugs shown to slow early Alzheimer's rather than just treat symptoms.

3. How well do these drugs work?

They slow decline modestly on average. In the Clarity AD trial, lecanemab showed a 0.45-point difference on the CDR-SB scale at 18 months. Donanemab showed a 3.25-point difference on the iADRS scale at 76 weeks in people with low or medium tau. Some researchers question whether the benefit is meaningful for every patient.

4. What are the main side effects?

The main concern is ARIA, which usually means brain swelling or small bleeds seen on MRI. In pivotal trials, ARIA-E occurred in 12.6% of people on lecanemab and 24.0% on donanemab. Doctors use regular MRI scans to watch for it.

5. Who can take these drugs?

They are for people in the early stages of Alzheimer's, such as mild cognitive impairment or mild dementia, with confirmed amyloid in the brain. Doctors also consider genetic risk (APOE) and overall health. They are not for everyone.

6. What is the new Alzheimer's blood test?

It measures markers like phosphorylated tau (pTau217) in a blood sample. In 2026, the FDA cleared Roche's Elecsys pTau217 test for adults 55 and older with cognitive symptoms. It helps rule in or rule out Alzheimer's-related amyloid changes, alongside a doctor's assessment.

7. Can a blood test diagnose Alzheimer's on its own?

No. The tests support a diagnosis but are not stand-alone answers. A doctor still needs to review symptoms, history, and other tests.

8. Is there a blood test for younger people?

Yes. The FDA-cleared PrecivityAD2 is intended for adults as young as 40 with memory or thinking symptoms. In a study of 1,142 symptomatic adults, it had a positive predictive value of 97.6% and a negative predictive value of 93.1%.

9. Can lifestyle changes really reduce dementia risk?

Research suggests up to 45% of dementia cases could be prevented or delayed by tackling 14 modifiable risk factors. These include high blood pressure, diabetes, high cholesterol, smoking, heavy drinking, inactivity, depression, social isolation, and air pollution. The WHO also advises against routine vitamin or omega-3 supplements unless a deficiency is diagnosed.

10. Why is trial diversity such a big deal?

Dementia clinical trials need tens of thousands of volunteers, and many groups are underrepresented. If trials do not include a wide mix of people, results may not apply to everyone, and safety issues can be missed. Fixes include community-based trials, culturally tailored materials, fair compensation, and local treatment sites.